新兴的跨导管心脏门技术用于严重的大动脉狭窄
Ahmed Elkoumy1,2,3, Darren Mylotte1, Hesham Elzomor1,2
1Department of Cardiology, Saolta Group, Galway University Hospital, Galway, Ireland.
Expert review of medical devices
|November 7, 2023
概括
新兴的跨导管心脏门 (THV) 解决了当前用于大动脉狭窄的跨导管大动脉植入 (TAVI) 的局限性. 新的THV旨在改善结果,并为不断增长的患者群体扩大TAVI的适应性.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 过导管大动脉植入 (TAVI) 是严重的大动脉狭窄症的标准治疗方法.
- 20多年来,TAVI在扩大患者标准方面面临着局限性和挑战.
- 人口老龄化将增加对大动脉置换手术的需求.
研究的目的:
- 审查新兴的通过导管的心脏门 (THVs) 用于大动脉狭窄治疗.
- 讨论解决当前TAVI局限性的创新,并扩大适应症.
- 探索旨在提高耐用性和新型患者解剖学的THV.
主要方法:
- 关于新兴THV技术的文献综述.
- 分析目前的TAVI局限性和挑战.
- 评估新的THV设计及其潜在应用.
主要成果:
- 新兴的THV旨在减少准膜泄漏和导电干扰.
- 新的设备可能使TAVI用于双大动脉,大动脉吐和复杂的解剖学.
- 一些新的THV被设计为解决生物假体门的长期耐用性.
结论:
- 随着THVs的不断变化的格局,它为当前的TAVI挑战提供了解决方案.
- 在THV技术的创新对于管理大动脉狭窄的日益增加的负担至关重要.
- 未来的THV有望扩大TAVI的适用性并改善患者的治疗结果.
更多相关视频
08:50Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
Published on: March 26, 2018
11.7K
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
2.9K
相关概念视频
Mitral Stenosis III: Medical Management
12
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
12
Aortic Regurgitation III: Medical Management
24
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
24
Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
22
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
22
